Loncar Cancer Immunotherapy Etf Profile
| CNCR Etf | USD 14.11 0.25 1.74% |
Performance3 of 100
| Odds Of DistressLess than 9
|
Loncar Cancer is selling at 14.11 as of the 19th of April 2024; that is -1.74 percent decrease since the beginning of the trading day. The etf's lowest day price was 13.92. Loncar Cancer has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Loncar Cancer Immunotherapy are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of March 2024 and ending today, the 19th of April 2024. Click here to learn more.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. More on Loncar Cancer Immunotherapy
Moving together with Loncar Etf
| 0.85 | XLV | Health Care Select | PairCorr |
| 0.83 | VHT | Vanguard Health Care | PairCorr |
| 0.85 | XBI | SPDR SP Biotech | PairCorr |
| 0.84 | IHI | iShares Medical Devices Sell-off Trend | PairCorr |
| 0.84 | IXJ | iShares Global Healthcare | PairCorr |
| 0.86 | IYH | iShares Healthcare ETF | PairCorr |
Moving against Loncar Etf
| 0.73 | AMPD | Tidal Trust II | PairCorr |
Loncar Etf Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Loncar Cancer's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Loncar Cancer or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Ideas | (View all Themes) |
| Business Concentration | Health Care ETFs, Sector ETFs, Robots And Drones, Health, Loncar Investments (View all Sectors) |
| Issuer | Exchange Traded Concepts |
| Inception Date | 2015-10-13 |
| Benchmark | Range Cancer Therapeutics Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 21.1 Million |
| Average Trading Valume | 28,668.9 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
| Region | North America |
| Administrator | U.S. Bancorp Fund Services, LLC |
| Advisor | Exchange Traded Concepts, LLC |
| Custodian | U.S. Bank, N.A. |
| Distributor | Quasar Distributors, LLC |
| Portfolio Manager | Denise M. Krisko |
| Transfer Agent | U.S. Bank, N.A. |
| Fiscal Year End | 30-Nov |
| Exchange | NASDAQ |
| Number of Constituents | 79.0 |
| Market Maker | Jane Street |
| Total Expense | 0.79 |
| Management Fee | 0.79 |
| Country Name | USA |
| Returns Y T D | 6.61 |
| Name | Loncar Cancer Immunotherapy ETF |
| Currency Code | USD |
| Open Figi | BBG00B55D0W8 |
| In Threey Volatility | 31.05 |
| 1y Volatility | 38.33 |
| 200 Day M A | 12.9904 |
| 50 Day M A | 16.1429 |
| Code | CNCR |
| Updated At | 19th of April 2024 |
| Currency Name | US Dollar |
Loncar Cancer Immunotherapy [CNCR] is traded in USA and was established 2015-10-13. The fund is listed under Health category and is part of Loncar Investments family. The entity is thematically classified as Health Care ETFs. Loncar Cancer Immuno currently have 20.52 M in assets under management (AUM). , while the total return for the last 3 years was -19.2%.
Check Loncar Cancer Probability Of Bankruptcy
Top Loncar Cancer Immunotherapy Etf Constituents
| NVS | Novartis AG ADR | Stock | Health Care |
| REGN | Regeneron Pharmaceuticals | Stock | Health Care |
| NXTC | NextCure | Stock | Health Care |
| IGMS | IGM Biosciences | Stock | Health Care |
| IOVA | Iovance Biotherapeutics | Stock | Health Care |
| GMAB | Genmab AS | Stock | Health Care |
| BLUE | Bluebird bio | Stock | Health Care |
Loncar Cancer Target Price Odds Analysis
In regard to a normal probability distribution, the odds of Loncar Cancer jumping above the current price in 90 days from now is about 90.35%. The Loncar Cancer Immunotherapy probability density function shows the probability of Loncar Cancer etf to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the etf has a beta coefficient of 2.397 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Loncar Cancer will likely underperform. Additionally, loncar Cancer Immunotherapy has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Loncar Cancer to move above the current price in 90 days from now is about 90.35 (This Loncar Cancer Immunotherapy probability density function shows the probability of Loncar Etf to fall within a particular range of prices over 90 days) .
Loncar Cancer Immuno Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Loncar Cancer market risk premium is the additional return an investor will receive from holding Loncar Cancer long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Loncar Cancer. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Loncar Cancer's alpha and beta are two of the key measurements used to evaluate Loncar Cancer's performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | 0.0313 | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.0092 |
Loncar Cancer Against Markets
Picking the right benchmark for Loncar Cancer etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Loncar Cancer etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Loncar Cancer is critical whether you are bullish or bearish towards Loncar Cancer Immunotherapy at a given time. Please also check how Loncar Cancer's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Loncar Cancer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
How to buy Loncar Etf?
Before investing in Loncar Cancer, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Loncar Cancer. To buy Loncar Cancer etf, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Loncar Cancer. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Loncar Cancer etf. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Loncar Cancer Immunotherapy etf in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Loncar Cancer Immunotherapy etf, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the etf
It's important to note that investing in stocks, such as Loncar Cancer Immunotherapy, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in etf prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Loncar Etf please use our How to Invest in Loncar Cancer guide.
Already Invested in Loncar Cancer Immunotherapy?
The danger of trading Loncar Cancer Immunotherapy is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Loncar Cancer is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Loncar Cancer. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Loncar Cancer Immuno is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Loncar Cancer Immuno is a strong investment it is important to analyze Loncar Cancer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Loncar Cancer's future performance. For an informed investment choice regarding Loncar Etf, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Loncar Cancer Immunotherapy. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Loncar Cancer Immuno information on this page should be used as a complementary analysis to other Loncar Cancer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.